{{Rsnum
|rsid=4253728
|Gene=PPARA
|Chromosome=22
|position=46214170
|Orientation=plus
|GMAF=0.135
|Gene_s=PPARA
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 9.7 | 34.5 | 55.8
| HCB | 0.0 | 0.0 | 100.0
| JPT | 0.0 | 0.0 | 100.0
| YRI | 0.0 | 3.4 | 96.6
| ASW | 0.0 | 14.3 | 85.7
| CHB | 0.0 | 0.0 | 100.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 1.0 | 13.9 | 85.1
| LWK | 0.0 | 3.7 | 96.3
| MEX | 3.4 | 19.0 | 77.6
| MKK | 0.6 | 12.2 | 87.2
| TSI | 6.9 | 52.0 | 41.2
| HapMapRevision=28
}}{{PMID Auto
|PMID=22510778
|Title=PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo
}}

{{PMID Auto
|PMID=24113216
|Title=Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-α are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus
}}

{{PMID Auto
|PMID=24353446
|Title=Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response
|OA=1
}}

{{PMID Auto
|PMID=18061194
|Title=Polymorphisms in the peroxisome proliferator activated receptor alpha gene are associated with levels of apolipoprotein CIII and triglyceride in African-Americans but not Caucasians.
|OA=1
}}

{{PMID Auto
|PMID=24921414
|Title=Impact of PPARA and POR polymorphisms on tacrolimus pharmacokinetics and new-onset diabetes in kidney transplant recipients
}}
{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}